Italia markets open in 6 hours 38 minutes

Vertex Pharmaceuticals Incorporated (0QZU.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
470,85-6,35 (-1,33%)
Alla chiusura: 06:49PM BST

Vertex Pharmaceuticals Incorporated

50 Northern Avenue
Boston, MA 02210
United States
617 341 6100
https://www.vrtx.com

Settore/i
Settore
Impiegati a tempo pieno5.400

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Jeffrey Marc Leiden M.D., Ph.D.Executive Chairman95,02kN/D1956
Dr. Reshma Kewalramani FASN, M.D.CEO, President & Director5,59M3,86M1973
Mr. Charles F. Wagner Jr.Executive VP & CFO2,12MN/D1968
Mr. Stuart A. Arbuckle B.Sc.Executive VP & COO2,76M3,21M1966
Dr. David M. Altshuler M.D., Ph.D.Executive VP & Chief Scientific Officer2,17M154,49k1965
Ms. Kristen C. Ambrose CPASenior VP & Chief Accounting OfficerN/DN/D1977
Mr. Mike TirozziSVP and Chief Information & Data OfficerN/DN/DN/D
Susie LisaSenior Vice President of Investor RelationsN/DN/DN/D
Mr. Jonathan Biller J.D.Executive VP & Chief Legal OfficerN/DN/D1964
Ms. Nina DevlinSenior VP & Chief Communications OfficerN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Vertex Pharmaceuticals Incorporated al 1 giugno 2024 è 8. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 6; diritti degli azionisti: 6; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.